Patents by Inventor Jiaqiang Cai

Jiaqiang Cai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210179647
    Abstract: The present invention relates to compounds represented by formula (I) and formula (II) and a chiral synthesis and chiral isolation method therefor, further relating to a salt and crystal form of the compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the preparation of a medicament used for the treatment of a viral infectious disease such as hepatitis B.
    Type: Application
    Filed: June 3, 2019
    Publication date: June 17, 2021
    Applicant: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    Inventors: Qiang TIAN, Tianming WANG, Wei LIU, Baolei ZHANG, Mingliang ZHAO, Yufeng LIANG, Jiaqiang CAI, Lichun WANG, Jingyi WANG
  • Publication number: 20210101906
    Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.
    Type: Application
    Filed: December 10, 2018
    Publication date: April 8, 2021
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jiaqiang CAI, Shuai SONG, Tongtong XUE, Liang XIAO, Hanwen DENG, Qiang TIAN, Jing WANG, Dengnian LIU, Liping Liu, Haimin YU, Zhouning YANG, Xu CAO, Guoqing ZHONG, Lichun WANG, Jingyi WANG
  • Publication number: 20210052576
    Abstract: Provided are tetrahydroisoquinoline derivatives, the preparation and use thereof. More specifically, provided are the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, isotopically labeled compound, metabolite or prodrug thereof. Further provided are a preparation process of the compound, the intermediates, a pharmaceutical composition comprising the compound and the use thereof in the treatment or prevention of a thromboembolic disorder.
    Type: Application
    Filed: March 18, 2019
    Publication date: February 25, 2021
    Inventors: Yongyong WU, Jiaqiang CAI, Guangchao ZHANG, Shuangshuang DUAN, Chaolei WANG, Lichun WANG, Jingyi WANG
  • Publication number: 20210040096
    Abstract: The present invention relates to Fused Tricyclic Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocyclic Compound, and methods of using the Fused Tricyclic Heterocyclic Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: October 27, 2020
    Publication date: February 11, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Tao Yu, Sherman T. Waddell, Thomas H. Graham, Yonglian Zhang, John A. McCauley, Andrew W. Stamford, Jiaqiang Cai, Zhiqi Qi
  • Publication number: 20210024514
    Abstract: Disclosed are a solid form of (E)-3-((R)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acrylic acid, a preparation method therefor, a pharmaceutical composition comprising same, and the use thereof in the preparation of drugs for preventing or treating viral diseases.
    Type: Application
    Filed: May 6, 2019
    Publication date: January 28, 2021
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: TIANMING WANG, CHENGXI YANG, JIAQIANG CAI, WEI LIU, BAOLEI ZHANG, QIANG TIAN, SHUAI SONG, HAO HU, WEIBIAO HAN, YOUQIANG LI, XING CHEN, LICHUN WANG, JINGYI WANG
  • Patent number: 10899786
    Abstract: Provided in the present invention are a compound of Formula (I), a pharmaceutical composition comprising the same, a method for preparing the same, and use thereof as a NS5B polymerase inhibitor, a DNA polymerase inhibitor or a reverse transcriptase inhibitor for the prevention or treatment of viral diseases or cancers.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: January 26, 2021
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jiaqiang Cai, Shuai Song, Qiang Tian, Yitao Zhang, Haitao Huang, Guoqing Zhong, Wei Zhong, Yongjia Hao, Mingliang Zhao, Hong Zeng, Hongmei Song, Xin Zhou, Yao Liu, Yuting Tan, Lichun Wang, Jingyi Wang
  • Publication number: 20200361911
    Abstract: Related is a nitrogen-containing benzoheterocycle compound containing a carboxylic acid group as shown in general formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. The compound has excellent pharmacokinetic properties and extremely remarkable liver targeting properties, and a pharmaceutical composition comprising the same may be used as a CCR antagonist, in particular a CCR2 and/or CCR5 antagonist and can be used in mediated disease, including, but not limited to, nonalcoholic fatty liver disease (NAFLD) or the like.
    Type: Application
    Filed: January 18, 2019
    Publication date: November 19, 2020
    Inventors: Shuai SONG, Qiang TIAN, Yongyong WU, Mingliang ZHAO, Chaolei WANG, Jiaqiang CAI, Lichun WANG, Jingyi WANG
  • Publication number: 20200347075
    Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.
    Type: Application
    Filed: December 10, 2018
    Publication date: November 5, 2020
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jiaqiang CAI, Shuai SONG, Tongtong XUE, Liang XIAO, Hanwen DENG, Qiang TIAN, Jing WANG, Dengnian LIU, Liping Liu, Haimin YU, Zhouning YANG, Xu CAO, Guoqing ZHONG, Lichun WANG, Jingyi WANG
  • Publication number: 20200339558
    Abstract: The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a polymorph, a solvate (e.g., a hydrate), a pharmaceutically acceptable salt, an ester, a metabolite, and an N-oxide, and the chemically protected forms and prodrugs thereof. The present invention further provides a preparation method for the compound, an intermediate thereof, and a pharmaceutical composition and kit containing the same and used thereof for treating FXR-mediated diseases or conditions.
    Type: Application
    Filed: December 7, 2018
    Publication date: October 29, 2020
    Applicant: SICHUAN KELUN-BiOTECH BIGPHARMACEUTICAL CO., LTD.
    Inventors: JINMING LIU, JIAQIANG CAI, YONGYONG WU, WEI YIN, LUCHUN WANG, JINGYI WANG
  • Publication number: 20200308214
    Abstract: Provided in the present invention are a compound of Formula (I), a pharmaceutical composition comprising the same, a method for preparing the same, and use thereof as a NS5B polymerase inhibitor, a DNA polymerase inhibitor or a reverse transcriptase inhibitor for the prevention or treatment of viral diseases or cancers.
    Type: Application
    Filed: December 19, 2017
    Publication date: October 1, 2020
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jiaqiang CAI, Shuai SONG, Qiang TIAN, Yitao ZHANG, Haitao HUANG, Guoqing ZHONG, Wei ZHONG, Yongjia HAO, Mingliang ZHAO, Hong ZENG, Hongmei SONG, Xin ZHOU, Yao LIU, Yuting TAN, Lichun WANG, Jingyi WANG
  • Publication number: 20200253971
    Abstract: The present invention relates to a method for prophylactically treating or treating a viral disease, comprising administering to a subject in need thereof a dihydropyrimidine compound, and the viral diseases include, but are not limited to, Hepatitis A, Hepatitis B, Hepatitis C, influenza, herpes and acquired immunodeficiency syndrome (AIDS).
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Shuai Song, Jiaqiang Cai, Qiang Tian, Hong Zeng, Hongmei Song, Hanwen Deng, Zujian Tang, Xiaofan Duan, Rongrong Long, Yao Liu, Lichun Wang, Jingyi Wang
  • Patent number: 10696669
    Abstract: The present invention relates to a dihydropyrimidine compound having an antiviral activity, a pharmaceutical composition comprising same, a preparation method therefor and the uses thereof in the prevention or treatment of viral diseases including, but not limited to, Hepatitis A, Hepatitis B, Hepatitis C, influenza, herpes and acquired immunodeficiency syndrome (AIDS).
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: June 30, 2020
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICALS CO., LTD.
    Inventors: Shuai Song, Jiaqiang Cai, Qiang Tian, Hong Zeng, Hongmei Song, Hanwen Deng, Zujian Tang, Xiaofan Duan, Rongrong Long, Yao Liu, Lichun Wang, Jingyi Wang
  • Publication number: 20200179529
    Abstract: Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3? molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.
    Type: Application
    Filed: April 12, 2018
    Publication date: June 11, 2020
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jiaqiang CAI, Tongtong XUE, Shuai SONG, Jing WANG, Qiang TIAN, Liang XIAO, Hanwen DENG, Liping LIU, Zujian TANG, Hong ZENG, Rongrong LONG, Hongmei SONG, Qiang ZHANG, Guoqing ZHONG, Dengnian LIU, Haitao HUANG, Ruibin HU, Lichun WANG, Jingyi WANG
  • Publication number: 20200121707
    Abstract: A pharmaceutical composition comprising a 4?-thionucleoside phosphamide derivative or a pharmaceutically acceptable salt, ester, hydrate, solvate, and isomer thereof, any crystalline form thereof or racemate, metabolite, or a combination of a mixture thereof with other drugs, and a method and use thereof for disease treatment and/or prevention.
    Type: Application
    Filed: August 24, 2018
    Publication date: April 23, 2020
    Inventors: Hongmei SONG, Hong ZENG, Xiaoda NIU, Ying WANG, Qiang TIAN, Daibiao XIAO, Jiaqiang CAI, Lichun WANG, Jingyi WANG
  • Publication number: 20200109166
    Abstract: The invention relates to a polyamide compound and a use thereof. Specifically, the invention relates to a type of polyamide compound (which preferably comprise one or more amide bonds formed by condensation of same or different L-amino acids or D-amino acids), or stereoisomers, crystalline polymorphs, solvates, metabolites, prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions thereof, as well as a method for preparing the polyamide compound and a use thereof in the prevention or treatment of diseases associated with ?-opioid receptor. The polyamide compound of the invention has excellent ?-opioid receptor agonistic activity and hydrophilicity, thus having a lesser ability of penetrating the blood-brain barrier and a lower capacity for entering the brain.
    Type: Application
    Filed: September 22, 2017
    Publication date: April 9, 2020
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jiaqiang CAI, Qiang TIAN, Mingliang ZHAO, Hong ZENG, Hongmei SONG, Nan YU, Hua DENG, Wei ZHONG, Long YANG, Lei WU, Haitao HUANG, Yongyong WU, Donghai SU, Xin ZHOU, Yuting TAN, Lichun WANG, Jingyi WANG
  • Publication number: 20190322666
    Abstract: The present invention relates to Fused Tricyclic Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocyclic Compound, and methods of using the Fused Tricyclic Heterocyclic Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 24, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Tao Yu, Sherman T. Waddell, Thomas H. Graham, Yonglian Zhang, John A. McCauley, Andrew W. Stamford, Jiaqiang Cai, Zhiqi Qi
  • Publication number: 20190315771
    Abstract: The present invention relates to novel 2-acylaminothiazole derivatives. The present invention also relates to the preparation method for these novel 2-acylaminothiazole derivatives and intermediates thereof, and a pharmaceutical composition containing these compounds. Moreover, the present invention also relates to these novel 2-acylaminothiazole derivatives and the pharmaceutical composition containing the same for use in treating and/or preventing thrombopoietin receptor mediated diseases.
    Type: Application
    Filed: August 31, 2017
    Publication date: October 17, 2019
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jiaqiang CAI, Nan YU, Hong ZENG, Hongmei SONG, Yan QING, Shuai SONG, Hanwen DENG, Zujian TANG, Xiaofan DUAN, Haitao HUANG, Hong YE, Gang LIU, Lichun WANG, Jingyi WANG
  • Publication number: 20190225603
    Abstract: The present invention relates to a dihydropyrimidine compound having an antiviral activity, a pharmaceutical composition comprising same, a preparation method therefor and the uses thereof in the prevention or treatment of viral diseases including, but not limited to, Hepatitis A, Hepatitis B, Hepatitis C, influenza, herpes and acquired immunodeficiency syndrome (AIDS).
    Type: Application
    Filed: November 9, 2017
    Publication date: July 25, 2019
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Shuai SONG, Jiaqiang CAI, Qiang TIAN, Hong ZENG, Hongmei SONG, Hanwen DENG, Zujian TANG, XIAOFAN DUAN, Rongrong LONG, Yao LIU, Lichun WANG, Jingyi WANG
  • Patent number: 10246457
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R7, R8 and R9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: April 2, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tony Siu, Michael D. Altman, Brian M. Andresen, Jian Liu, Joseph Kozlowski, Sobhana Babu Boga, Younong Yu, Rajan Anand, Jiaqiang Cai, Dahai Wang, Shilan Liu
  • Patent number: 10233193
    Abstract: The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, m, R1, R2, R3, R3, R3, R4, R5 and R9 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: March 19, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tao Yu, Thomas H. Graham, Sherman T. Waddell, John A. McCauley, Andrew W. Stamford, John M. Sanders, Lihong Hu, Jiaqiang Cai, Lianyun Zhao